ERBB2 and breast carcinoma: ROC AUC and Mann-Whitney analyses demonstrate that MAF1 (AUC = 0.754, p = 0.017) altered expression in neratinib-treated HER2-positive breast cancer cell lines in the CTRP dataset, lower vs. upper tertile of AUDRC [74].